Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types Colorectal cancer affects over 150,000 new patients in the U.S. annually, with many patients ...

"The collaboration with Tempus will substantially augment our existing precision oncology capabilities. Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage ...

Personalis (PSNL) and Tempus AI (TEM) announced that the companies have expanded their commercial relationship.The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD ...

Tempus AI's partnerships with NYU Langone and Northwestern Medicine aim to expand genomic testing and data-driven cancer care ...

We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other ...

Tempus AI TEM is leaning into a dual-engine model: a fast-growing Genomics franchise and a scaling data business powered by an expanding AI toolkit. The third quarter of 2025 marked a turn to non-GAAP ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed ...

Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate ...

CEO Christopher Hall reported Q1 2025 revenue of $20.6 million, marking a strong start to the year. He highlighted significant progress in their "Win-in-MRD" strategy, driven by demand for the company ...

Chicago artificial intelligence giant Tempus AI is showing it's operating in the black after 10 years and growing.